Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q3

9987.TEDINET S100Q7UC
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥1.76T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥24.4bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥12.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥27.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥15.4bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥27.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥18.7bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥18.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥13.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥18.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥13.3bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.30Tat 2022-12-31Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.29Tat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥891.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥412.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥419.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥169.8bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥208.462022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.022021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥170.6bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥30.1bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥140.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.5bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.69T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.65T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥38.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥20.3bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥25.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.96T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.76T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥205.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥24.3bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥136.4bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥29.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥107.0bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥20m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.6bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥1.62T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.58T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥40.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥7.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥9.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥24.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥1.86T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥171.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥12.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 354
ItemContextValueUnit
Profit loss attributable to non controlling interestsCurrentYTDDuration-23000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration13244000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration18161000000JPY
Profit lossPrior1YTDDuration13327000000JPY
Profit lossCurrentYTDDuration18137000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-1034000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration1549000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration23000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration73000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-194000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration-196000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YTDDuration384000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYTDDuration823000000JPY
Other comprehensive incomePrior1YTDDuration-821000000JPY
Other comprehensive incomeCurrentYTDDuration2249000000JPY
Comprehensive incomePrior1YTDDuration12506000000JPY
Comprehensive incomeCurrentYTDDuration20387000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration12423000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration20410000000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration82000000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration-23000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember1583181000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember9453000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember66822000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember29483000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember1688941000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember40089000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember24533000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember20000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember106958000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember171602000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember1623271000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember33987000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember66843000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember136441000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember1860543000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember7002000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember2376000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember1650000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember1847000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember12876000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember1653903000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember8239000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember65633000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember30148000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember1757925000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember38809000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02780-000ThePharmaceuticalManufacturingBusinessReportableSegmentsMember25796000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02780-000TheInsurancePharmacyBusinessReportableSegmentsMember10000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember140460000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass